Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Telomere-associated chromatin is a specialized nucleoprotein structure located at the termini of eukaryotic chromosomes, primarily composed of repetitive DNA sequences (TTAGGG in humans) and the six-protein shelterin complex (de Lange, 2005, Genes & Development). This chromatin structure is essential for maintaining genomic integrity by masking chromosome ends from the DNA damage response machinery, thereby preventing deleterious end-to-end fusions and degradation (O'Sullivan & Karlseder, 2010, Nature Reviews Molecular Cell Biology). It also regulates the access of telomerase, the enzyme responsible for extending telomeres, which is a critical factor in cellular immortality (Blackburn, 2001, Nature). In the context of disease, telomere-associated chromatin is frequently dysregulated; cancer cells often exploit telomere maintenance mechanisms to achieve unlimited proliferative potential, while telomere shortening is a hallmark of aging and various telomeropathies like Dyskeratosis congenita (Armanios & Blackburn, 2012, Nature Reviews Genetics). Therapeutic targeting of this chromatin involves the use of G-quadruplex stabilizers, which lock telomeric DNA into structures that inhibit telomerase, or small molecules designed to disrupt shelterin proteins like TRF2 (Neidle, 2017, Nature Reviews Chemistry). Such interventions aim to induce telomere crisis, leading to selective apoptosis or senescence in malignant cells.
Stabilization of G-quadruplex structures to prevent telomerase binding, disruption of the shelterin complex to induce telomere dysfunction, and inhibition of telomerase enzymatic activity to promote telomere shortening.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Telomere-associated chromatin.